Healthcare Industry News: stomach cancer
News Release - December 30, 2014
Lightpoint Medical Raises £2 Million in Series A Funding Round
RICKMANSWORTH, England, December 30, 2014 -- (Healthcare Sales & Marketing Network) --Lightpoint Medical, a developer of innovative surgical imaging technologies, announced today that the company has raised £2 million ($3.1 million) in a Series A financing round. Investors included Oxford Technology and leading business angel networks Cambridge Capital Group, London Business Angels, Envestors, Ruffena Capital, and crowdfunding platform SyndicateRoom.Dr David Tuch, CEO of Lightpoint Medical, commented "We're delighted to have secured funding from previous investors Oxford Technology as well as from some of the leading angel networks in the UK. This equity investment complements our substantial grant funding from FP7 and Innovate UK and our development contract with SBRI Healthcare. The funding will help bring our two lead products to market and more importantly transform the lives of cancer patients."
Goncalo de Vasconcelos, CEO of SyndicateRoom commented, "Lightpoint Medical attracted an enormous amount of interest from SyndicateRoom investors due to both the investment opportunity and the quality of the management team. It came without a surprise that the funding round was completely oversubscribed."
"Being an investor in Lightpoint has been a pleasure," remarked Lucius Cary, Managing Director of Oxford Technology. "From the initial investment, everything has gone better than expected. This happens only rarely. In Lightpoint's case, the technology has worked. More grants have been received than initially hoped. It has been easy to attract new investors. Most importantly, surgeons have been enthusiastic about using the technology since it has the potential to dramatically improve outcomes for their patients."
About Lightpoint Medical
Lightpoint Medical is an innovative medical device company dedicated to improving health outcomes for cancer patients through image-guided surgery. The company's ground-breaking molecular imaging technology, based on Cerenkov Luminescence, has the potential to detect cancer in real-time during surgery and thereby reduce the need for repeat operations. For more information contact info@lightpointmedical.com or visit http://www.lightpointmedical.com
Source: Lightpoint Medical
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
